The BRWD1 Knockout SK-HEP-1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal population of human SK-HEP-1 hepatic adenocarcinoma cells with disrupted BRWD1 gene. This pool retains genetic diversity, offering a loss-of-function model for chromatin remodeling studies without clonal bias. It enables systematic dissection of BRWD1??s roles in transcriptional regulation and B cell development pathways in an epithelial liver cancer context.
SK-HEP-1 cells originate from a hepatic adenocarcinoma of a 52-year-old male. Though classified as liver adenocarcinoma, they display endothelial-like features and are used as liver sinusoidal endothelial models. This line exhibits metastatic potential and is widely employed to study hepatic tumor biology and cancer cell signaling. Its hybrid phenotype makes it a valuable platform for exploring how transcriptional co-regulators like BRWD1 affect liver cancer progression and metastasis.
BRWD1 is a bromodomain-containing transcriptional co-regulator that binds acetylated histones and the SWI/SNF complex to remodel chromatin. It functions downstream of PAX5 and EBF1, and is activated by NF-??B and PI3K/AKT signaling. BRWD1 promotes expression of B cell lineage genes, cell cycle regulators, and apoptosis-related genes. Through SWI/SNF, it links extracellular signals to chromatin reorganization critical for B cell development and hematopoiesis. In SK-HEP-1 cells, its disruption may alter chromatin states and gene expression outside the hematopoietic lineage.
Although BRWD1 is traditionally linked to B cell development and hematologic malignancies, its knockout in a hepatic adenocarcinoma model offers a unique system to study tissue-specific functions. SK-HEP-1??s endothelial-like and metastatic characteristics allow exploration of chromatin-mediated regulation of migration, invasion, and drug sensitivity. The polyclonal knockout pool minimizes clonal artifacts, enabling robust high-throughput screening in cancer biology.
These polyclonal BRWD1 knockout SK-HEP-1 cells support diverse applications: ChIP-qPCR and RNA-seq for chromatin and transcriptome analysis; RT-qPCR and Western blotting for targeted gene and protein expression studies; flow cytometry and proliferation/migration assays to assess functional impacts. They are ideal for drug sensitivity profiling to identify compounds selectively active against BRWD1-deficient cells, aiding synthetic lethal interaction discovery. Please contact Ascent Research for technical support.
